Modified mRNA as a therapeutic option in cardiac regeneration
Szabó Gábor Tamás
Debreceni Egyetem, Kardiológiai és Szívsebészeti Klinika, Debrecen
Cardiovascular diseases including heart failure are the leading causes of death in the industrialized countries and their prevention and treatment are one of the challenging tasks for cardiologists. In spite of the significant effort to improve both life expectancy and quality of life of patients suffering from these diseases, no widely available and effective treatment exists for the replacement of lost cardiomyocytes. The adult human heart has a very low regenerative capacity. In the past years, data had surfaced from various experimental and clinical research indicating that cardiomyocyte protection, angioneogenesis, as well as cardiomyocyte proliferation are all feasible via the modification of different signaling mechanisms. Observations deriving from stem cell experiments highlighted the advantages of cell-free therapies. For instance, gene therapy is a great avenue to replace proteins necessary for cardiac regeneration at a desired concentration. Delivery of genetic information to the appropriate cells with modified mRNA is a promising and safe way to ensure transient and well-controlled protein secretion and immunogenicity.